NCT05685303
Alleviant ALLAY-HF Study
Enrolling by Invitation
NAAges 40+InterventionalTreatmentAlleviant Medical, Inc.
~700 participants
Updated 2026-05-04 on ClinicalTrials.gov
What's tested:Alleviant ALV1 SystemSham-Control
At a glance
Recruiting sites
0 of 97 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Composite Primary Endpoint
Measured over 12-month
Conditions
Where it's being run
97 sites across 42 statesGermany9
Spain7
California6
Poland6
Florida5
New York5
Texas5
Illinois3
Study leadership
- James Udelson, MD · PRINCIPAL_INVESTIGATOR · Tufts Medical Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Composite Primary Endpoint12-month
The primary endpoint is a composite of mortality, heart failure events and quality of life based on Kansas City Cardiomyopathy Questionnaire (KCCQ) calculated at 12 months. KCCQ responses are provided along a rating scale from 0-100 with a higher score indicating better health.